CRISPR Stock: Bull vs. Bear
CRISPR Therapeutics (NASDAQ: CRSP) works in the cutting-edge space of gene editing. The biotech company uses the CRISPR/Cas9 technique, which involves cutting DNA at a certain point and letting a natural repair process take place. It's a way to "fix" faulty genes involved in disease.
The company doesn't yet have a product on the market, but that soon may be about to change. Is now the moment to get in on this gene editing specialist? Motley Fool contributors Adria Cimino and Keith Speights discuss the bull and bear cases.
Adria Cimino: CRISPR has reached the most exciting moment in its story as a company so far. Along with partner Vertex Pharmaceuticals, CRISPR has completed regulatory submissions in the U.S., Europe, and the U.K. for what may become its first commercialized product.
Source Fool.com
